文献速递心血管胸部技术与安全CTMR

动脉粥样硬化性心血管疾病筛查的先进影像生物标志物

State-of-the-Art Imaging Biomarkers in Screening of Atherosclerotic Cardiovascular Disease.
PubMed 文献 · Radiographics · 2026-01-01

本文综述影像生物标志物在动脉粥样硬化性心血管疾病筛查中的作用。冠状动脉钙化积分是最成熟且获指南认可的再分层指标,冠脉CT血管成像通过斑块负荷、成分及高危特征提供增量预后信息。常规CT和MRI中的机会性标志物可在不增加辐射的情况下扩展心血管风险评估。

要点

  • 冠状动脉钙化积分是非增强心电门控CT中最成熟的危险再分层影像标志物。
  • 冠脉CT血管成像可评估斑块负荷、成分和高危斑块特征,提供增量预后信息。
  • 常规CT和MRI中偶然发现的心外钙化、肝脂肪变、内脏肥胖等机会性标志物可用于心血管风险评估。

核心结论

  • 影像生物标志物可直接检测和量化亚临床动脉粥样硬化,弥补传统风险模型在临界和中危患者中的不足。
  • 将影像生物标志物与临床危险因素、标准化报告和人工智能整合,有望改善ASCVD风险分层并实现更精准的心血管预防。

研究设计与样本

  • 本文为Radiographics发表的综述,回顾动脉粥样硬化性心血管疾病影像生物标志物的证据、指南推荐和临床价值。
  • 涵盖冠状动脉钙化积分、冠脉CT血管成像、定量斑块分析、冠状动脉周围脂肪、颈动脉和主动脉成像、心外膜脂肪及动脉僵硬度等影像学方法。

关键影像表现/征象

  • 冠状动脉钙化积分在非增强心电门控CT上检测冠脉钙化,是风险再分类中最成熟的影像生物标志物。
  • 冠脉CT血管成像可显示斑块负荷、斑块成分和高危斑块特征,定量斑块分析和冠状动脉周围脂肪可进一步反映斑块生物学和炎症活动。
  • 常规CT和MRI中的机会性标志物包括偶然发现的冠状动脉和心外钙化、乳腺动脉钙化、肝脂肪变、内脏肥胖、肌肉减少症、骨质疏松和脑影像标志物。

诊断标准与关键数值

  • 传统风险预测模型在临界风险和中危患者中可能低估或高估个体风险,不足以单独指导预防性治疗决策。
  • 冠状动脉钙化积分是获得指南认可用于风险再分类的影像生物标志物,其评估基于非增强心电门控CT。
  • 冠状动脉CT血管成像通过评估斑块负荷、斑块成分和高危斑块特征提供比单纯钙化积分更多的预后信息。

临床应用与阅片要点

  • 在临界和中危患者中,冠状动脉钙化积分可用于风险再分类并辅助预防性治疗决策。
  • 报告常规CT和MRI时,应关注并报告偶然发现的心血管相关机会性标志物,如心外钙化、乳腺动脉钙化、肝脂肪变和内脏肥胖。
  • 许多新兴影像生物标志物需要进一步标准化和基于结局的验证后,才能常规应用于临床风险分层。

局限性

  • 许多新兴影像生物标志物仍需进一步标准化和基于结局的验证。
  • 传统风险预测模型在临界风险和中危患者中可能低估或高估个体风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Atherosclerotic cardiovascular disease (ASCVD) is the leading global cause of death and evolves over decades through a prolonged subclinical phase, providing a critical opportunity for early detection and prevention. Traditional risk prediction models estimate future cardiovascular risk but may under- or overestimate individual risk, particularly in borderline- and intermediate-risk patients, making them insufficient to guide preventive therapy decisions. Imaging biomarkers complement clinical risk assessment by directly detecting and quantifying subclinical atherosclerosis, enabling more personalized preventive strategies. Coronary artery calcium (CAC) scoring with noncontrast electrocardiographic (ECG)-gated CT remains the most established and guideline-endorsed imaging biomarker for risk reclassification. Coronary CT angiography provides incremental prognostic information through assessment of plaque burden, plaque composition, and high-risk plaque features, while emerging techniques, including quantitative plaque analysis and pericoronary adipose assessment, further characterize plaque biology and inflammatory activity. Beyond coronary imaging, extracoronary biomarkers, including carotid and aortic imaging, epicardial adipose tissue, and arterial stiffness assessments provide complementary information about systemic vascular and cardiometabolic health. In addition, opportunistic biomarkers identified at routine CT and MRI examinations, such as incidental coronary and extracoronary calcifications, breast arterial calcification, hepatic steatosis, visceral adiposity, sarcopenia, osteoporosis, and cerebral imaging markers, expand opportunities for cardiovascular risk assessment without additional imaging or radiation. Although many emerging biomarkers require further standardization and outcome-based validation, integration of imaging biomarkers with clinical risk factors, standardized reporting, and artificial intelligence has the potential to improve ASCVD risk stratification and enable more precise and personalized cardiovascular prevention.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Sorin, Fatade, Morris, et al. State-of-the-Art Imaging Biomarkers in Screening of Atherosclerotic Cardiovascular Disease. Radiographics. 2026. PMID: 42784472. doi:10.1148/rg.260068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。